Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy
ObjectiveThe present study aimed to evaluate the predictive factors that predict outcomes of HER2-low breast cancer patients who did not achieve pathological complete response(pCR) after neoadjuvant chemotherapy (NAC).MethodsThis study included patients with HER2-low breast cancer who received NAC f...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1459444/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850070625100496896 |
|---|---|
| author | Yingbo Shao Yingbo Shao Huijuan Guan Huijuan Guan Zhifen Luo Zhifen Luo Yang Yu Yang Yu Yaning He Yaning He Qi Chen Qi Chen Chaojun Liu Chaojun Liu Fangyuan Zhu Fangyuan Zhu Hui Liu Hui Liu |
| author_facet | Yingbo Shao Yingbo Shao Huijuan Guan Huijuan Guan Zhifen Luo Zhifen Luo Yang Yu Yang Yu Yaning He Yaning He Qi Chen Qi Chen Chaojun Liu Chaojun Liu Fangyuan Zhu Fangyuan Zhu Hui Liu Hui Liu |
| author_sort | Yingbo Shao |
| collection | DOAJ |
| description | ObjectiveThe present study aimed to evaluate the predictive factors that predict outcomes of HER2-low breast cancer patients who did not achieve pathological complete response(pCR) after neoadjuvant chemotherapy (NAC).MethodsThis study included patients with HER2-low breast cancer who received NAC from January 2017 to December 2020. Analysis of the clinicopathological features, NAC response and outcome of the patients were retrospectively analyzed. Univariate and multivariable Cox analysis were used to determine factors that predict outcomes of HER2-low breast cancer patients who did not exhibit pCR.Results293 Asian patients were included. The proportion of patients with hormone receptor (HR) positive and triple negative breast cancer (TNBC) among HER2-low patients was 75.8% and 24.2%, respectively. The pCR rate of HR positive cases was significantly lower than TNBC (27.5% vs. 53.5%, P=0.000). The patients who obtained pCR after NAC showed better disease-free survival(DFS) (5-year DFS 93.9% vs. 83.1%, p=0.039). For patients not achieving pCR, multivariable analysis showed that Miller/Payne (MP) grading system (hazard ratio: 0.094; 95% CI: 0.037-0.238; p=0.000) and HR status (hazard ratio: 2.561; 95% CI: 1.100-5.966; p=0.029) were significant independent predictors for DFS. Additionally, The MP grading system was also an independent predictor of overall survival (OS) (hazard ratio: 0.071; 95% CI: 0.019-0.260; p=0.000).ConclusionsThe results of our study show that pathological assessment following NAC offers valuable insights into the survival outcome of HER2-low breast cancer. According to these findings, responses to NAC should be considered when choosing systemic treatment for patients with HER2-low breast cancer. |
| format | Article |
| id | doaj-art-ea5b05332b8d471493dcee94dcfe088f |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-ea5b05332b8d471493dcee94dcfe088f2025-08-20T02:47:28ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-03-011510.3389/fonc.2025.14594441459444Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapyYingbo Shao0Yingbo Shao1Huijuan Guan2Huijuan Guan3Zhifen Luo4Zhifen Luo5Yang Yu6Yang Yu7Yaning He8Yaning He9Qi Chen10Qi Chen11Chaojun Liu12Chaojun Liu13Fangyuan Zhu14Fangyuan Zhu15Hui Liu16Hui Liu17Department of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Pathology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Pathology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Medical Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Medical Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, ChinaDepartment of Breast Oncology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, Henan, ChinaObjectiveThe present study aimed to evaluate the predictive factors that predict outcomes of HER2-low breast cancer patients who did not achieve pathological complete response(pCR) after neoadjuvant chemotherapy (NAC).MethodsThis study included patients with HER2-low breast cancer who received NAC from January 2017 to December 2020. Analysis of the clinicopathological features, NAC response and outcome of the patients were retrospectively analyzed. Univariate and multivariable Cox analysis were used to determine factors that predict outcomes of HER2-low breast cancer patients who did not exhibit pCR.Results293 Asian patients were included. The proportion of patients with hormone receptor (HR) positive and triple negative breast cancer (TNBC) among HER2-low patients was 75.8% and 24.2%, respectively. The pCR rate of HR positive cases was significantly lower than TNBC (27.5% vs. 53.5%, P=0.000). The patients who obtained pCR after NAC showed better disease-free survival(DFS) (5-year DFS 93.9% vs. 83.1%, p=0.039). For patients not achieving pCR, multivariable analysis showed that Miller/Payne (MP) grading system (hazard ratio: 0.094; 95% CI: 0.037-0.238; p=0.000) and HR status (hazard ratio: 2.561; 95% CI: 1.100-5.966; p=0.029) were significant independent predictors for DFS. Additionally, The MP grading system was also an independent predictor of overall survival (OS) (hazard ratio: 0.071; 95% CI: 0.019-0.260; p=0.000).ConclusionsThe results of our study show that pathological assessment following NAC offers valuable insights into the survival outcome of HER2-low breast cancer. According to these findings, responses to NAC should be considered when choosing systemic treatment for patients with HER2-low breast cancer.https://www.frontiersin.org/articles/10.3389/fonc.2025.1459444/fullbreast cancerneoadjuvant chemotherapyHER2-low expressionpathological complete responseprognosis |
| spellingShingle | Yingbo Shao Yingbo Shao Huijuan Guan Huijuan Guan Zhifen Luo Zhifen Luo Yang Yu Yang Yu Yaning He Yaning He Qi Chen Qi Chen Chaojun Liu Chaojun Liu Fangyuan Zhu Fangyuan Zhu Hui Liu Hui Liu Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy Frontiers in Oncology breast cancer neoadjuvant chemotherapy HER2-low expression pathological complete response prognosis |
| title | Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy |
| title_full | Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy |
| title_fullStr | Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy |
| title_full_unstemmed | Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy |
| title_short | Predictive factors for outcome in HER2-low breast cancer patients after neoadjuvant chemotherapy |
| title_sort | predictive factors for outcome in her2 low breast cancer patients after neoadjuvant chemotherapy |
| topic | breast cancer neoadjuvant chemotherapy HER2-low expression pathological complete response prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1459444/full |
| work_keys_str_mv | AT yingboshao predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT yingboshao predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT huijuanguan predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT huijuanguan predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT zhifenluo predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT zhifenluo predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT yangyu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT yangyu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT yaninghe predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT yaninghe predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT qichen predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT qichen predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT chaojunliu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT chaojunliu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT fangyuanzhu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT fangyuanzhu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT huiliu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy AT huiliu predictivefactorsforoutcomeinher2lowbreastcancerpatientsafterneoadjuvantchemotherapy |